Filing Details
- Accession Number:
- 0001209191-18-005831
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-01-29 16:19:55
- Reporting Period:
- 2018-01-25
- Accepted Time:
- 2018-01-29 16:19:55
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1566044 | Menlo Therapeutics Inc. | MNLO | Pharmaceutical Preparations (2834) | 453757789 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1627363 | Remeditex Ventures Llc | 2727 North Harwood, Suite 200 Dallas TX 75201 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2018-01-25 | 100,000 | $17.00 | 1,582,854 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2018-01-29 | 2,650 | $0.00 | 1,585,504 | No | 4 | C | Direct | |
Common Stock | Acquisiton | 2018-01-29 | 871,583 | $0.00 | 2,457,087 | No | 4 | C | Direct | |
Common Stock | Acquisiton | 2018-01-29 | 304,576 | $0.00 | 2,761,663 | No | 4 | C | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct | |
No | 4 | C | Direct | |
No | 4 | C | Direct | |
No | 4 | C | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Series A Preferred Stock | Disposition | 2018-01-29 | 7,150 | $0.00 | 2,650 | $0.00 |
Common Stock | Series B Preferred Stock | Disposition | 2018-01-29 | 2,351,097 | $0.00 | 871,583 | $0.00 |
Common Stock | Series C Preferred Stock | Disposition | 2018-01-29 | 821,596 | $0.00 | 304,576 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | C | Direct | ||
0 | No | 4 | C | Direct | ||
0 | No | 4 | C | Direct |
Footnotes
- Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of the Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into 0.3707 shares of the Issuer's common stock.